Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation

Translational Psychiatry

Volumn 6, Issue 10, 2016, Pages

  Parrott, J M ^a,b   Redus, L ^a   Santana Coelho, D ^a,b   Morales, J ^a   Gao, X ^a   O'Connor, J C ^a,b,c  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3-HYDROXYANTHRANILIC ACID OXIDASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; LIPOPOLYSACCHARIDE; OXIDOREDUCTASE;

ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DEPRESSION; DRUG EFFECTS; FEMALE; HIPPOCAMPUS; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOTOR ACTIVITY; MOUSE;

ANIMALS; DEPRESSION; FEMALE; HIPPOCAMPUS; INFLAMMATION; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; OXIDOREDUCTASES;

EID: 84999947490     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.200     Document Type: Article

References (62)

1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
2. Capuron L, Miller AH. Cytokines and psychopathology: Lessons from inter- feron-alpha. Biol Psychiatry 2004; 56: 819-824.
3. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010; 68: 748-754.
4. Grigoleit JS, Kullmann JS, Wolf OT, Hammes F, Wegner A, Jablonowski S et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One 2011; 6: E28330.
5. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008; 63: 1022-1029.
6. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009; 66: 407-414.
7. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness beha¬vior, and anhedonia. J Neuroinflammation 2008; 5: 15.
8. Konsman JP, Veeneman J, Combe C, Poole S, Luheshi GN, Dantzer R. Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. Eur J Neurosci 2008; 28: 2499-2510.
9. O’Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J et al. Interferon- gamma and tumor necrosis factor-alpha mediate the upregulation of indolea- mine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009; 29: 4200-4209.
10. Capuron L, Miller AH. Immune system to brain signaling: Neuropsychopharma- cological implications. Pharmacol Ther 2011; 130: 226-238.
11. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune sys¬tems. Nat Rev Immunol 2011; 11: 625-632.
12. Andre C, O’Connor JC, Kelley KW, Lestage J, Dantzer R, Castanon N. Spatio- temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopoly- saccharide administration. J Neuroimmunol 2008; 200: 90-99.
13. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryp¬tophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538-544.
14. O’Connor JC, Lawson MA, Andre C, Moreau M, Lestage J, Castanon N et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511-522.
15. O’Connor JC, Lawson MA, Andre C, Briley EM, Szegedi SS, Lestage J etal. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009; 182: 3202-3212.
16. Salazar A, Gonzalez-Rivera BL, Redus L, Parrott JM, O’Connor JC. Indoleamine 2,3- dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Hormones Behav 2012; 62: 202-209.
17. Corona AW, Norden DM, Skendelas JP, Huang Y, O’Connor JC, Lawson M et al. Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice. Brain Behav Immun 2013; 31: 134-142.
18. Lawson MA, Parrott JM, McCusker RH, Dantzer R, Kelley KW, O’Connor JC. Intra- cerebroventricular administration oflipopolysaccharide induces indoleamine-2,3- dioxygenase-dependent depression-like behaviors. J Neuroinflamm 2013; 10: 87.
19. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: Relationship to CNS immune responses and depression. Mol Psy¬chiatry 2010; 15: 393-403.
20. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depres¬sive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013; 38: 1609-1616.
21. Zeisel A, Munoz-Manchado AB, Codeluppi S, Lonnerberg P, La Manno G, Jureus A et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 2015; 347: 1138-1142.
22. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3- dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005; 49: 15-23.
23. Ganong AH, Cotman CW. Kynurenic acid and quinolinic acid act at N-methyl-D- aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther 1986; 236: 293-299.
24. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: Physiopathological implica¬tions. J Neurosci 2001; 21: 7463-7473.
25. Saito K, Markey SP, Heyes MP. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 1992; 51: 25-39.
26. Lugo-Huitron R, Ugalde Muniz P, Pineda B, Pedraza-Chaverri J, Rios C, Perez-de la Cruz V. Quinolinic acid: An endogenous neurotoxin with multiple targets. Oxida¬tive Med Cell Longevity 2013; 2013: 104024.
27. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: When physiology meets pathology. Nat Rev Neurosci 2012; 13: 465-477.
28. Parrott JM, O’Connor JC. Kynurenine 3-monooxygenase: An influential mediator of neuropathology. Front Psychiatry 2015; 6: 116.
29. Miller AH. Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypoth¬eses of depression. Neuropsychopharmacology 2013; 38: 1607-1608.
30. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56.
31. Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR etal. Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat Methods 2009; 6: 493-495.
32. Skarnes WC, Auerbach BA, Joyner AL. A gene trap approach in mouse embryonic stem cells: The lacZ reported is activated by splicing, reflects endogenous gene expression, and is mutagenic in mice. Genes Dev 1992; 6: 903-918.
33. Heisler JM, O’Connor JC. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav Immun 2015; 50: 115-124.
34. Parrott JM, Redus L, O’Connor JC. Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge. J Neuroin¬flammation 2016; 13: 124.
35. Franklin KBJ, Paxinos G. The Mouse Brain in Sterotaxic Coordinates. 3rd edn, Aca¬demic Press: New York, NY, 2007.
36. Copeland CS, Neale SA, Salt TE. Actions of xanthurenic acid, a putative endo¬genous Group II metabotropic glutamate receptor agonist, on sensory transmis¬sion in the thalamus. Neuropharmacology 2013; 66: 133-142.
37. Neale SA, Copeland CS, Uebele VN, Thomson FJ, Salt TE. Modulation of hippocampal synaptic transmission by the kynurenine pathway member xanthurenic acid and otherVGLUT inhibitors. Neuropsychopharmacology 2013; 38: 1060-1067.
38. Frenois F, Moreau M, O’Connor J, Lawson M, Micon C, Lestage J et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007; 32: 516-531.
39. Giorgini F, Huang SY, Sathyasaikumar KV, Notarangelo FM, Thomas MA, Tararina M et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem 2013; 288: 36554-36566.
40. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007; 33: 797-804.
41. Chess AC, Landers AM, Bucci DJ. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res 2009; 201: 325-331.
42. Varga D, Heredi J, Kanvasi Z, Ruszka M, Kis Z, Ono E et al. Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice. Front Behav Neurosci 2015; 9: 157.
43. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K etal. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748-751.
44. Insel TR. The NIMH Research Domain Criteria (RDoC) Project: Precision medicine for psychiatry. Am J Psychiatry 2014; 171: 395-397.
45. Leppanen JM. Emotional information processing in mood disorders: A review of behavioral and neuroimaging findings. Curr Opin Psychiatry 2006; 19: 34-39.
46. Shirayama Y, Chaki S. Neurochemistry ofthe nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol 2006; 4: 277-291.
47. McKinnon MC, Yucel K, Nazarov A, MacQueen GM. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34: 41-54.
48. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: Implications for neurocircuitry models of depression. Brain Struct Funct 2008; 213: 93-118.
49. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005; 29: 571-625.
50. Sharma S, Rakoczy S, Brown-Borg H. Assessment of spatial memory in mice. Life Sci 2010; 87: 521-536.
51. Kim CS, Chang PY, Johnston D. Enhancement of dorsal hippocampal activity by knockdown of HCN1 channels leads to anxiolytic- and antidepressant-like behaviors. Neuron 2012; 75: 503-516.
52. Davis M. Neurobiology of fear responses: The role of the amygdala. J Neuro- psychiatr Clin Neurosci 1997; 9: 382-402.
53. Prut L, Belzung C. The open field as a paradigm to measure the effects ofdrugs on anxiety-like behaviors: A review. Eur J Pharmacol 2003; 463: 3-33.
54. Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci 2016; 19: 504-516.
55. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guillemin GJ et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immunity 2015; 43: 110-117.
56. Georgin-Lavialle S, Moura DS, Salvador A, Chauvet-Gelinier JC, Launay JM, Damaj G et al. Mast cells’ involvement in inflammation pathways linked to depression: Evidence in mastocytosis. Mol Psychiatry 2016; 21: 1511-1516.
57. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015; 40: 463-471.
58. Linderholm KR, Andersson A, Olsson S, Olsson E, Snodgrass R, Engberg G et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis. Neuropharmacology 2007; 53: 918-924.
59. Nilsson LK, Linderholm KR, Erhardt S. Subchronic treatment with kynurenine and probenecid: Effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm 2006; 113: 557-571.
60. Wu HQ, Rassoulpour A, Schwarcz R. Kynurenic acid leads, dopamine follows: A new case of volume transmission in the brain? J Neural Trans 2007; 114: 33-41.
61. Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 2006; 170: 326-332.
62. Gal EM, Sherman AD. L-kynurenine: Its synthesis and possible regulatory function in brain. Neurochem Res 1980; 5: 223-239.